What's in the Latest Issue?
Thinking Like an Owner
Bob Desmond and Adam Chandler of Claremont Funds Management describe the entry points they eventually find into high-quality businesses, their no-business-school-awards approach to valuation, why they think being based far from New York is an advantage, and why they see unrecognized value in Dassault Systemes, Zoetis and CME Group.
Going Through a Phase
River Global Investors' Hugh Sergeant, William Lough, George Ensor and James Sym explain why they target ideas at different stages in their company lifecycles, how they’ve learned to guard against “falling knives,” how they’ve become selectively more activist, and why they think Danieli, Shaftesbury Capital, Clarkson and Henry Schein are mispriced.
Getting Down to Business
Scott Miller of Greenhaven Road Capital describes how he targets companies that appear to be misunderstood by the market, why he has “different types of bets” in his portfolio, how he deals psychologically with highly volatile performance, and why he sees ample prospective upside in off-the-radar companies like Hagerty, Burford Capital and Cellebrite.
Uncovering Value: Royalty Pharma
An opportunity to benefit from broad-based innovation without the typical attendant risks?
Editor's Letter
On avoiding "What was I thinking?" types of mistakes.
Investment Highlights
Royalty Pharma, Burford Capital, Cellebrite, Clarkson, CME Group, Danieli, Dassault Systemes, Hagerty, Henry Schein, Shaftesbury Capital, Zoetis
Other Companies in this Issue:
Agilent, Alibaba, Aon, Equifax, Estee Lauder, Fevertree Drinks, IWG, Kenvue, Louisiana-Pacific, LVMH, M.J. Gleeson, Nike, Par Technology, SAP, Tsubakimoto Chain